Peter Thiel's Uncomplimentary Views on Big Pharma - Science
paperCredibility Rating
Gold standard. Rigorous peer review, high editorial standards, and strong institutional reputation.
Rating inherited from publication venue: Science
A 2014 blog post with limited direct AI safety relevance; tangentially useful for discussions of institutional incentives, innovation stagnation, and how incumbent industries resist technological change—themes that parallel debates about AI deployment and incumbent tech firms.
Metadata
Summary
Derek Lowe responds to Peter Thiel's 2014 claim that pharmaceutical companies are 'bets against innovation,' arguing they are better characterized as indifferent to innovation rather than actively anti-innovation. Lowe acknowledges valid concerns about large pharma prioritizing M&A, patent extensions, and share buybacks over R&D, while defending genuine research efforts like Eli Lilly's Alzheimer's program. The piece engages Thiel's broader thesis about technological stagnation in modern capitalism.
Key Points
- •Thiel argues large pharma companies are fundamentally anti-innovation, primarily extending patents and blocking smaller competitors rather than developing new treatments.
- •Lowe counters that big pharma is better described as 'indifferent' to innovation—preferring to maximize existing assets via line extensions and acquisitions over risky R&D.
- •Share buybacks are highlighted as particularly concerning, diverting capital that could fund research into propping up share prices instead.
- •Eli Lilly's aggressive Alzheimer's research is cited as evidence that major pharma companies do pursue genuine high-risk innovation, complicating Thiel's blanket critique.
- •Thiel's broader argument about capital misallocation—funding social media over medical research—is acknowledged as having real merit despite oversimplifying pharma specifically.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Peter Thiel (Funder) | Organization | 63.0 |
Cached Content Preview
Peter Thiel's Uncomplimentary Views of Big Pharma | Science | AAAS
Mar
APR
May
28
2024
2025
2026
success
fail
About this capture
COLLECTED BY
Collection: Save Page Now Outlinks
TIMESTAMPS
The Wayback Machine - http://web.archive.org/web/20250428213541/https://www.science.org/content/blog-post/peter-thiel-s-uncomplimentary-views-big-pharma
Skip to main content
news
careers
commentary
Journals
Log in
Science.
Become a AAAS Member today and receive:
Breaking news from Science
Weekly Policy Alerts impacting STEM
Exclusive member-focused content
Unlimited access to our online AAAS Member Community
Discounts with a variety of AAAS partners
And much more!
">Become A Member
science
science advances
science immunology
science robotics
science signaling
science translational medicine
science partner journals
Quick Search anywhere
Enter Search Term
Quick Search in Journals
Enter Search Term
Quick Search in Journals
Enter Search Term
Quick Search in Journals
Enter Search Term
Quick Search in Journals
Enter Search Term
Quick Search in Journals
Enter Search Term
Quick Search in Journals
Enter Search Term
Searching:
Anywhere
AnywhereScienceScience AdvancesScience ImmunologyScience RoboticsScience SignalingScience Translational Medicine
Advanced Search
Search
Trending Terms:
cancer
climate
artificial intelligence
postdoc
aging
Log In
Donate
Quick Search anywhere
Enter Search Term
science.org
Custom publishing
prizes and awards
newsletters
collections
videos
podcasts
blogs
visualizations
authors & reviewers
librarians
advertisers
about
help
Terms of Service
Privacy Policy
Accessibility
Commentary Home
Opinion
Analysis
Blogs
GET OUR E-ALERTS
Main content starts here
HomeCommentaryBlogsIn the PipelinePeter Thiel's Uncomplimentary Views of Big Pharma
Back To In the Pipeline
In the Pipeline
Business and Markets
... (truncated, 13 KB total)7865641bab4711d8 | Stable ID: sid_sYBZu43fWT